Status:
COMPLETED
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics
Conditions:
Biomarker
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.
Eligibility Criteria
Inclusion
- Male or female patients, ≥18 to ≤75 years of age;
Exclusion
- Presence of, or history of cancer, with the exception of completely excised, non-metastatic squamous cell or basal cell carcinomas of the skin;
- Has a clinically significant systemic infection (e.g., chronic or acute infection, UTI, URI) within 30 days of Day 0, or a history or presence of recurrent or chronic infection (e.g. viral infections, \[including hepatitis B or C, HIV\], bacterial infections, systemic fungal infections, or syphilis);
- Subjects with a history of coronary events within the last 6 months;
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2011
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT01159730
Start Date
October 1 2010
End Date
October 1 2011
Last Update
November 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VBL Investigative Site
Glasgow, Scotland, United Kingdom